---
title: "Psilocybin compound achieves two positive Phase 3 results in treating depression - potential breakthrough in CNS disorders."
description: "Helus Pharma, based in Vancouver, BC, announced on February 26, 2026, the groundbreaking development that the first psilocybin compound has successfully obtained two positive Phase 3 results for treat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277077934.md"
published_at: "2026-02-26T17:10:15.000Z"
---

# Psilocybin compound achieves two positive Phase 3 results in treating depression - potential breakthrough in CNS disorders.

> Helus Pharma, based in Vancouver, BC, announced on February 26, 2026, the groundbreaking development that the first psilocybin compound has successfully obtained two positive Phase 3 results for treating treatment-resistant depression. This significant achievement could mark a transformative change in the approach to managing depression. This breakthrough holds the promise of offering a new treatment option for patients struggling with depression.

Helus Pharma, based in Vancouver, BC, announced on February 26, 2026, the groundbreaking development that the first psilocybin compound has successfully obtained two positive Phase 3 results for treating treatment-resistant depression. This significant achievement could mark a transformative change in the approach to managing depression. This breakthrough holds the promise of offering a new treatment option for patients struggling with depression.

### Related Stocks

- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [LONA.US - LeonaBio](https://longbridge.com/en/quote/LONA.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [HEPA.US - Hepion Pharmaceuticals](https://longbridge.com/en/quote/HEPA.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AbbVie announces $380m investment in North Chicago API facilities | AbbVie has announced a $380 million investment in its North Chicago API facilities, set to integrate advanced manufactur | [Link](https://longbridge.com/en/news/276714948.md) |
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/en/news/277123919.md) |
| Dror Ortho-Design, Inc. SEC 10-K Report | Dror Ortho-Design, Inc. has released its annual 10-K report, detailing its financial performance and strategic initiativ | [Link](https://longbridge.com/en/news/277226243.md) |
| Soleno Therapeutics reports FY profit for 2025 | Soleno Therapeutics reported a profitable FY 2025 with a net income of $20.9 million, driven by Q4 revenue of $91.7 mill | [Link](https://longbridge.com/en/news/276938001.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/en/news/277046688.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.